Bayesian estimation of cost-effectiveness ratios from clinical trials
- PMID: 10348414
- DOI: 10.1002/(sici)1099-1050(199905)8:3<191::aid-hec409>3.0.co;2-r
Bayesian estimation of cost-effectiveness ratios from clinical trials
Abstract
Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials.
Similar articles
-
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.Health Econ. 1999 May;8(3):203-11. doi: 10.1002/(sici)1099-1050(199905)8:3<203::aid-hec413>3.0.co;2-7. Health Econ. 1999. PMID: 10348415
-
Bayesian estimation of cost-effectiveness from censored data.Stat Med. 2004 Apr 30;23(8):1297-309. doi: 10.1002/sim.1740. Stat Med. 2004. PMID: 15083484
-
A Bayesian approach to stochastic cost-effectiveness analysis.Health Econ. 1999 May;8(3):257-61. doi: 10.1002/(sici)1099-1050(199905)8:3<257::aid-hec427>3.0.co;2-e. Health Econ. 1999. PMID: 10348420
-
Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.Health Econ. 1997 Jul-Aug;6(4):327-40. doi: 10.1002/(sici)1099-1050(199707)6:4<327::aid-hec282>3.0.co;2-w. Health Econ. 1997. PMID: 9285227 Review.
-
Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial.Eur J Gastroenterol Hepatol. 2004 Jun;16(6):543-9. doi: 10.1097/00042737-200406000-00006. Eur J Gastroenterol Hepatol. 2004. PMID: 15167155 Review.
Cited by
-
Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.Stat Methods Med Res. 2021 May;30(5):1306-1319. doi: 10.1177/0962280221995972. Epub 2021 Apr 7. Stat Methods Med Res. 2021. PMID: 33826460 Free PMC article.
-
Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds.Int J Environ Res Public Health. 2020 May 28;17(11):3823. doi: 10.3390/ijerph17113823. Int J Environ Res Public Health. 2020. PMID: 32481604 Free PMC article.
-
Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.Pharmacoeconomics. 2000 Apr;17(4):339-49. doi: 10.2165/00019053-200017040-00004. Pharmacoeconomics. 2000. PMID: 10947489 Review.
-
Joint distribution approaches to simultaneously quantifying benefit and risk.BMC Med Res Methodol. 2006 Oct 12;6:48. doi: 10.1186/1471-2288-6-48. BMC Med Res Methodol. 2006. PMID: 17038184 Free PMC article.
-
Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers.PLoS One. 2021 Sep 20;16(9):e0257494. doi: 10.1371/journal.pone.0257494. eCollection 2021. PLoS One. 2021. PMID: 34543330 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical